Historical Valuation
AC Immune SA (ACIU) is now in the Fair zone, suggesting that its current forward PS ratio of 5.55 is considered Fairly compared with the five-year average of -6.70. The fair price of AC Immune SA (ACIU) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：3.44
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
AC Immune SA (ACIU) has a current Price-to-Book (P/B) ratio of 4.30. Compared to its 3-year average P/B ratio of 2.00 , the current P/B ratio is approximately 115.05% higher. Relative to its 5-year average P/B ratio of 1.89, the current P/B ratio is about 127.29% higher. AC Immune SA (ACIU) has a Forward Free Cash Flow (FCF) yield of approximately -18.11%. Compared to its 3-year average FCF yield of -11.62%, the current FCF yield is approximately 55.81% lower. Relative to its 5-year average FCF yield of -16.13% , the current FCF yield is about 12.26% lower.
P/B
Median3y
2.00
Median5y
1.89
FCF Yield
Median3y
-11.62
Median5y
-16.13
Competitors Valuation Multiple
AI Analysis for ACIU
The average P/S ratio for ACIU competitors is 8.37, providing a benchmark for relative valuation. AC Immune SA Corp (ACIU.O) exhibits a P/S ratio of 5.55, which is -33.68% above the industry average. Given its robust revenue growth of -96.32%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ACIU
1Y
3Y
5Y
Market capitalization of ACIU increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ACIU in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ACIU currently overvalued or undervalued?
AC Immune SA (ACIU) is now in the Fair zone, suggesting that its current forward PS ratio of 5.55 is considered Fairly compared with the five-year average of -6.70. The fair price of AC Immune SA (ACIU) is between to according to relative valuation methord.
What is AC Immune SA (ACIU) fair value?
ACIU's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of AC Immune SA (ACIU) is between to according to relative valuation methord.
How does ACIU's valuation metrics compare to the industry average?
The average P/S ratio for ACIU's competitors is 8.37, providing a benchmark for relative valuation. AC Immune SA Corp (ACIU) exhibits a P/S ratio of 5.55, which is -33.68% above the industry average. Given its robust revenue growth of -96.32%, this premium appears unsustainable.
What is the current P/B ratio for AC Immune SA (ACIU) as of Jan 09 2026?
As of Jan 09 2026, AC Immune SA (ACIU) has a P/B ratio of 4.30. This indicates that the market values ACIU at 4.30 times its book value.
What is the current FCF Yield for AC Immune SA (ACIU) as of Jan 09 2026?
As of Jan 09 2026, AC Immune SA (ACIU) has a FCF Yield of -18.11%. This means that for every dollar of AC Immune SA’s market capitalization, the company generates -18.11 cents in free cash flow.
What is the current Forward P/E ratio for AC Immune SA (ACIU) as of Jan 09 2026?
As of Jan 09 2026, AC Immune SA (ACIU) has a Forward P/E ratio of -6.21. This means the market is willing to pay $-6.21 for every dollar of AC Immune SA’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for AC Immune SA (ACIU) as of Jan 09 2026?
As of Jan 09 2026, AC Immune SA (ACIU) has a Forward P/S ratio of 5.55. This means the market is valuing ACIU at $5.55 for every dollar of expected revenue over the next 12 months.